search
Back to results

Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome

Primary Purpose

Sjögren's Syndrome

Status
Unknown status
Phase
Phase 2
Locations
Taiwan
Study Type
Interventional
Intervention
SS-1
Placebo
Sponsored by
China Medical University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sjögren's Syndrome focused on measuring Sjögren's syndrome, Gan-Lu-Yin, Sang-Ju-Yin, Xuefu-Zhuyu-Decoction, Oxidative stress, Immune regulation, Gene modulation, SS-1

Eligibility Criteria

20 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Primary or Secondary Sjögren's syndrome patient
  • Age from 20 to 75 year old, male or female patient
  • Fit the criteria of 2002 year American-European classification
  • If the subject took Cyclosporine, Cevimeline, Pilocarpine, Rituximab or other biological agent before enter into our study, the subject need to stop these drugs for one month
  • If the subject took Gan-Lu-Yin, Sang- Ju-Yin or Xuefu-Zhuyu-Decoction before enter into our study, the subject need to stop these drugs for one month
  • Secondary Sjögren's syndrome patient:

    • Stable treatment: Steroid (≦10mg/d) and fixed hydroxychloroquine dose before 3 months enrolled
    • No abnormal change of immunology, liver, kidney, and blood function
    • No major life threatened condition

Exclusion Criteria:

  • Alcohol abuse, DM (Glucose PC>200mg/dL) and major life threatened condition
  • Pregnancy or breast feeding
  • Abnormal liver and kidney function
  • Forbid steroid pulse therapy before 3 months enrolled into our study, and forbid the Chinese herbal medicine except SS-1

Sites / Locations

  • Taoyuan Chang Gung Memorial HospitalRecruiting
  • China Medical University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

SS-1

Placebo

Arm Description

SS-1 is composed of the powder of Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. Patients take 6 gram of experiment medicine three times per day.

The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.

Outcomes

Primary Outcome Measures

Ocular surface disease index (OSDI)
OSDI is an questionnaire of dry eye.
EULAR Sjogren's syndrome patient reported index (ESSPRI)
ESSPRI is an questionnaire of dry, pain and fatigue.
Sjogren's syndrome symptoms Questionnaire
Sjogren's syndrome symptoms Questionnaire is an questionnaire of dry month.
Schirmer's test
Schirmer's test is an objective detection of dry eye, which this test use paper strips inserted into the eye for 5 minutes to measure the production of tears.
Salivary scintigraphy
Salivary scintigraphy is an objective detection of dry month, which is used to detect the salivary flow in parotid gland of Sjogren's syndrome.

Secondary Outcome Measures

Oxidative stress and antioxidant capacity
To evaluate the effect of the SS-1 on the oxidative stress and antioxidant capacity. The "relative ratio" is the unit of these biomarkers for oxidative stress and antioxidant capacity
Quality of life (SF-36)
Regulatory effect on cytokine
To evaluate the effect of the SS-1 on the cytokine. The "pg/ml" is the unit of these biomarkers for oxidative stress and antioxidant capacity
Nanostring nCounter immune Panel
To evaluate the effect of the SS-1 on the immunity-related gene expression. Nanostring nCounter immune Panel is a tool for detecting the immunity-related gene expression.

Full Information

First Posted
July 13, 2016
Last Updated
August 1, 2016
Sponsor
China Medical University Hospital
Collaborators
Chang Gung Memorial Hospital, China Medical University, China, National Research Program for Biopharmaceuticals, Taiwan
search

1. Study Identification

Unique Protocol Identification Number
NCT02855658
Brief Title
Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome
Official Title
Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
August 2016
Overall Recruitment Status
Unknown status
Study Start Date
February 2014 (undefined)
Primary Completion Date
October 2016 (Anticipated)
Study Completion Date
April 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
China Medical University Hospital
Collaborators
Chang Gung Memorial Hospital, China Medical University, China, National Research Program for Biopharmaceuticals, Taiwan

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To evaluate the modulation of immunity-related gene expression for the Sjögren's syndrome under Chinese herbal medicine (SS-1) treatment.
Detailed Description
Objective: To evaluate the modulation of immunity-related gene expression for the Sjögren's syndrome under Chinese herbal medicine (SS-1) treatment. Method: The evidence of the regulation of oxidative-related cytokines and the antioxidant capacity could be provided from the previous randomized, double-blinded, placebo-controlled, cross-over design, two-center clinical trial for evaluating the effect of Chinese herbal medicine (SS-1) for the Sjögren's syndrome patients. However, the clinical trail could not find out the modulation of immunity-related gene expression for SS-1 treatment, and it did set up a healthy control group for SS-1 comparison. This study want to establish a healthy control group for evaluating the normal range of oxidative stress and cytokines, which this work could be used to compare with the 72 SS-1 subjects in previous study. And This study also want to analyze the 770 immunity-related gene expression for the Sjögren's syndrome under the SS-1 treatment: (1) The best 20 (at least) efficacy SJS subjects who were evaluated before and after SS-1 treatments. (2) The 10 (at least) healthy control subjects. The findings could provide the evidence on the modulation of immunity-related gene expression for clinical manifestation, oxidative stress and cytokine in Sjögren's syndrome patients. Expected Results: Establish the normal range of oxidative stress and cytokines for healthy control group. To evaluate the regulatory effect on oxidative stress and cytokine secretion between SS-1 group and healthy control group. To evaluate the immunity-related gene expression for the Sjögren's syndrome under the SS-1 treatment. To evaluate the immunity-related gene expression among the best efficacy SJS subjects and healthy control subjects. To evaluate the immunity-related gene expression with the characteristic of TCM tongue diagnosis. To analyze the correlation among clinical manifestations, Sjögren's syndrome -related clinical questionnaires and immunity-related gene expression.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sjögren's Syndrome
Keywords
Sjögren's syndrome, Gan-Lu-Yin, Sang-Ju-Yin, Xuefu-Zhuyu-Decoction, Oxidative stress, Immune regulation, Gene modulation, SS-1

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
90 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SS-1
Arm Type
Experimental
Arm Description
SS-1 is composed of the powder of Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. Patients take 6 gram of experiment medicine three times per day.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
Intervention Type
Drug
Intervention Name(s)
SS-1
Other Intervention Name(s)
Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction
Intervention Description
The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12 weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12 weeks SS-1 treatment. SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
1% SS-1
Intervention Description
The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
Primary Outcome Measure Information:
Title
Ocular surface disease index (OSDI)
Description
OSDI is an questionnaire of dry eye.
Time Frame
7 months
Title
EULAR Sjogren's syndrome patient reported index (ESSPRI)
Description
ESSPRI is an questionnaire of dry, pain and fatigue.
Time Frame
7 months
Title
Sjogren's syndrome symptoms Questionnaire
Description
Sjogren's syndrome symptoms Questionnaire is an questionnaire of dry month.
Time Frame
7 months
Title
Schirmer's test
Description
Schirmer's test is an objective detection of dry eye, which this test use paper strips inserted into the eye for 5 minutes to measure the production of tears.
Time Frame
7 months
Title
Salivary scintigraphy
Description
Salivary scintigraphy is an objective detection of dry month, which is used to detect the salivary flow in parotid gland of Sjogren's syndrome.
Time Frame
7 months
Secondary Outcome Measure Information:
Title
Oxidative stress and antioxidant capacity
Description
To evaluate the effect of the SS-1 on the oxidative stress and antioxidant capacity. The "relative ratio" is the unit of these biomarkers for oxidative stress and antioxidant capacity
Time Frame
7 months
Title
Quality of life (SF-36)
Time Frame
7 months
Title
Regulatory effect on cytokine
Description
To evaluate the effect of the SS-1 on the cytokine. The "pg/ml" is the unit of these biomarkers for oxidative stress and antioxidant capacity
Time Frame
7 months
Title
Nanostring nCounter immune Panel
Description
To evaluate the effect of the SS-1 on the immunity-related gene expression. Nanostring nCounter immune Panel is a tool for detecting the immunity-related gene expression.
Time Frame
7 months
Other Pre-specified Outcome Measures:
Title
Adverse effect (AE) and Adverse drug reaction(ADR)
Description
Monitor the Adverse effect (AE) and Adverse drug reaction(ADR) during the SS-1 trial.
Time Frame
7 months
Title
Liver, Kidney and Blood function monitor
Description
Monitor the Liver, Kidney and Blood function monitor (RBC, WBC, Hb, Platelet, AST, ALT, BUN, Cre) of patient during the SS-1 trial, and the different units are listed below: WBC (1000/uL), RBC (million/uL), Hb (g/dL), Platelet (1000/uL), AST (U/L), ALT (U/L), BUN (mg/dL), Serum Creatinine (mg/dL).
Time Frame
7 months
Title
Traditional Chinese medicine (TCM) tongue diagnosis
Description
To evaluate the effect of the SS-1 on the TCM tongue diagnosis before and after treatment.
Time Frame
7 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Primary or Secondary Sjögren's syndrome patient Age from 20 to 75 year old, male or female patient Fit the criteria of 2002 year American-European classification If the subject took Cyclosporine, Cevimeline, Pilocarpine, Rituximab or other biological agent before enter into our study, the subject need to stop these drugs for one month If the subject took Gan-Lu-Yin, Sang- Ju-Yin or Xuefu-Zhuyu-Decoction before enter into our study, the subject need to stop these drugs for one month Secondary Sjögren's syndrome patient: Stable treatment: Steroid (≦10mg/d) and fixed hydroxychloroquine dose before 3 months enrolled No abnormal change of immunology, liver, kidney, and blood function No major life threatened condition Exclusion Criteria: Alcohol abuse, DM (Glucose PC>200mg/dL) and major life threatened condition Pregnancy or breast feeding Abnormal liver and kidney function Forbid steroid pulse therapy before 3 months enrolled into our study, and forbid the Chinese herbal medicine except SS-1
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hen-Hong Chang, M.D., Ph.D.
Phone
+886-3196200
Ext
2677
Email
tcmchh55@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Ching-Mao Chang, M.D.
Phone
+886-919074951
Email
magicbjp@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hen-Hong Chang, M.D., Ph.D.
Organizational Affiliation
China Medical University Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Taoyuan Chang Gung Memorial Hospital
City
Gueishan Township
ZIP/Postal Code
333
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kuang-Hui Yu, M.D.
Email
goutyu@gmail.com
First Name & Middle Initial & Last Name & Degree
Shue-Fen Luo, M.D.
First Name & Middle Initial & Last Name & Degree
Jr-Rung Lin, Ph.D.
First Name & Middle Initial & Last Name & Degree
Yau-Huei Wei, Ph.D.
First Name & Middle Initial & Last Name & Degree
Ching-Mao Chang, M.D., Ph.D.
First Name & Middle Initial & Last Name & Degree
Kuang-Hui Yu, M.D.
Facility Name
China Medical University Hospital
City
Taichung
ZIP/Postal Code
404
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hen-Hong Chang, M.D., Ph.D.
Phone
+886-4-22053366
Ext
3501
Email
tcmchh55@gmail.com
First Name & Middle Initial & Last Name & Degree
Ching-Mao Chang, M.D.
Phone
886
First Name & Middle Initial & Last Name & Degree
Hen-Hong Chang, M.D., Ph.D.

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
25923413
Citation
Chang CM, Chu HT, Wei YH, Chen FP, Wang S, Wu PC, Yen HR, Chen TJ, Chang HH. The Core Pattern Analysis on Chinese Herbal Medicine for Sjogren's syndrome: A Nationwide Population-Based Study. Sci Rep. 2015 Apr 29;5:9541. doi: 10.1038/srep09541. Erratum In: Sci Rep. 2015;5:14887. Sci Rep. 2017 May 25;7:46824.
Results Reference
result
Links:
URL
https://clinicaltrials.gov/ct2/show/study/NCT02110446
Description
NCT02110446: Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome (SS-1)

Learn more about this trial

Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome

We'll reach out to this number within 24 hrs